Instil Bio Inc. (TIL) - Total Liabilities
Based on the latest financial reports, Instil Bio Inc. (TIL) has total liabilities worth $89.66 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Instil Bio Inc. to assess how effectively this company generates cash.
Instil Bio Inc. - Total Liabilities Trend (2019–2025)
This chart illustrates how Instil Bio Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check Instil Bio Inc. asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Instil Bio Inc. Competitors by Total Liabilities
The table below lists competitors of Instil Bio Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Top High Image
TWO:3284
|
Taiwan | NT$1.40 Billion |
|
Kronos Bio Inc
NASDAQ:KRON
|
USA | $28.33 Million |
|
Metair
JSE:MTA
|
South Africa | ZAC10.13 Billion |
|
Hwail Pharmaceutical Co.Ltd
KQ:061250
|
Korea | ₩5.29 Billion |
|
Airmate Cayman International Co Ltd
TW:1626
|
Taiwan | NT$5.27 Billion |
|
Botnia Gold AB (publ)
ST:BOTX
|
Sweden | Skr51.21 Million |
|
Kingston Resources Ltd
AU:KSN
|
Australia | AU$37.58 Million |
|
Wiener Privatbank SE
VI:WPB
|
Austria | €277.66 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Instil Bio Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TIL market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 39.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Instil Bio Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Instil Bio Inc. (2019–2025)
The table below shows the annual total liabilities of Instil Bio Inc. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $89.66 Million | -4.75% |
| 2024-12-31 | $94.13 Million | -5.68% |
| 2023-12-31 | $99.80 Million | -15.80% |
| 2022-12-31 | $118.52 Million | +116.35% |
| 2021-12-31 | $54.78 Million | +105.61% |
| 2020-12-31 | $26.64 Million | +1776.41% |
| 2019-12-31 | $1.42 Million | -- |
About Instil Bio Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as … Read more